Novozymes reported disappointing Q2 2023 results, with a 2% decline in revenue and a 4.2% drop in EBIT. The growth was driven by a positive performance in the BioEnergy segment, which was partly offset by the weakness in other areas. The downward revision to the FY2023 top-line outlook reflects the demand challenges and end-consumer trends. Although the BioEnergy momentum was something of a silver lining, the company may find it difficult to meet even its lowered targets, with little evidence of ....
